Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and Mortality

Abstract

PCV13 has brought greater benefits than we had expected in our setting. We observed a further decline on IPD incidence shortly after the shift from PCV7 to PCV13 in the national immunization program. This decline was accompanied by a substantial population-level decline in pneumococcal-related mortality of nearly 30% among nonvaccinated persons.

Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world

“…There were 9 studies reporting serotype distribution data among adults aged 65 y and older with IPD 5,6,18,24,[55][56][57][58][59] and another 3 with similar data on non-IPD conditions (Table 2). [60][61][62] Conjugate vaccine serotypes (i.e., serotypes included in PCV13) causing IPD among older adults were highly prevalent (> 60% of serotypes) in only 2 studies, one Polish 6 and one Spanish.…”

Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults

“…Profound reductions in adult IPD from pediatric PCV7 and PCV13 National Immunization Programs (NIPs), through herd protection, have been regularly described. [6][7][8][9] For nonbacteremic pneumococcal CAP, however, the data do not permit similar conclusions. In fact, recent work from the United Kingdom, 10 United States, 11,12 and Spain, 13 as well as data from the CommunityAcquired Pneumonia immunization Trial in Adults document persistent circulation of PCV7 and PCV13 serotypes in patients with confirmed pneumococcal CAP several years after successful NIP implementation, suggesting that IPD cohorts are not accurate surrogates for CAP.…”

Meningitis neumocóccica por serotipo 19 A, de curso fatal: ¿Un caso prevenible?

“…Éste es un serotipo inmunológicamente complejo; se postula que su cápsula es capaz de evadir al sistema inmune. En países con vacuna conjugada 13-valente, que incluye el serotipo 3, se ha visto una protección sub-óptima para este serotipo 10 . Estudios epidemiológicos realizados en algunos estados, como Calgary y Alaska 11,12 , que han incorporado esquema de vacunación con PCV-13, han demostrado una disminución en la portación nasofaríngea reduciendo de 19,9% a 13,3%.…”